When was Precision BioSciences founded?

Precision BioSciences was founded in 2006 and raised its 1st funding round 2 years after it was founded.

Where is Precision BioSciences located?

Precision BioSciences is headquartered in Durham, United States. It is registered at Durham, North Carolina.

Who is the current CEO of Precision BioSciences?

Matthew Kane of Precision BioSciences.

How many employees does Precision BioSciences have?

As of Mar 31, 2026, the latest employee count at Precision BioSciences is 97.

Is Precision BioSciences a funded company?

Precision BioSciences is a funded company, having raised a total of $136M across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Feb 12, 2008.

When was the latest funding round of Precision BioSciences?

Precision BioSciences' latest funding was a $***** Post IPO round on Mar 03, 2026, with participation from 0 investor.

What is the annual revenue of Precision BioSciences?

Annual revenue of Precision BioSciences is $34.3M as on Dec 31, 2025.

Where does Precision BioSciences rank among its competitors?

Precision BioSciences ranks 86th amongst 3389 active competitors, of which 1185 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Precision BioSciences, which secured an undisclosed amount in Mar, 2026.

Who are the top competitors of Precision BioSciences?

Precision BioSciences' top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Precision BioSciences secured the most recent funding round in March, 2026.

Precision BioSciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.

Website: precisionbiosciences.com
Registered Address: Durham, North Carolina

Key Metrics

Founded Year

2006

Location

Durham, United States

Stage

Public

Total Funding

$136M in 9 rounds

Latest Funding Round

Post IPO, Mar 03, 2026, $*****

Investors

VenBio & 30 more

Ranked

86^th among 3389 active competitors

Annual Revenue

$34.3M as on Dec 31, 2025

Employee Count

97 as on Mar 31, 2026

Similar Companies

Juno Therapeutics & 926 more

Exit Details

Public

View Precision BioSciences' full profile

Precision BioSciences is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Precision Biosciences, Inc. CIN: 20201021772 , United States, Active	Jan 08, 2020	-	-	-
PRECISION BIOSCIENCES INC CIN: 1357874 , United States, Active	Jan 25, 2006	$34.3M (As on Dec 31, 2025)	-	-
Precision Biosciences, Inc. CIN: 204206017 , United States, Active	Dec 26, 999	-	113 (As on Dec 31, 2024)	-

Precision BioSciences got listed on Mar 28, 2019.

Click here to take a look at Precision BioSciences's IPO in detail

Precision BioSciences has raised a total funding of $136M over 9 rounds. Its first funding round was on Feb 12, 2008. Precision BioSciences has 31 institutional investors.

Here is the list of recent funding rounds of Precision BioSciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 03, 2026	7713586	Post IPO	4149757	3158277	6925175	6313475
Jun 24, 2022	7832848	Post IPO	6122425	8737485	2366149	Novartis
Mar 14, 2019	5932763	Conventional Debt	5828945	9690998	6882363	6171557

Access funding benchmarks and valuations. Sign up today!

View details of Precision BioSciences's funding rounds and investors

Precision BioSciences' employee count trend

Precision BioSciences has 97 employees as of Mar 26. Here is Precision BioSciences's employee count trend over the years:

Employee count trend for Precision BioSciences

Uncover Precision BioSciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Precision BioSciences include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Precision BioSciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
6th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
86th	Precision BioSciences 2006, Durham (United States), Public	Developer of gene editing therapies to treat rare genetic diseases	$136M	RA Capital Management, Amgen Business Development ... & 29 others	57/100